Updates on the Management of Male Breast Cancer

Video
Conference|San Antonio Breast Cancer Symposium (SABCS)

This video highlights four abstracts from SABCS investigating the use of hereditary gene panels and methods to predict prognosis in male breast cancer.

In this video, N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, highlights four abstracts investigating the use of hereditary gene panels and methods to predict prognosis in male breast cancer.

Henry was a discussant for a spotlight session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
Related Content
Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Targeted Therapy First Strategy Reduces Need for Chemotherapy in Newly Diagnosed LBCL

Kristie L. Kahl
December 7th 2025
Article

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.

What Benefit Does Zanubrutinib Provide in Relapsed/Refractory CLL/SLL?

Kyle Doherty
December 7th 2025
Article

The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Azacitidine plus venetoclax reduced the risk of progressive disease, persistent disease prompting therapy change, relapse, hospice, or death by 45%.

Azacitidine Plus Venetoclax Improves EFS in Acute Myeloid Leukemia

Jonah Feldman
December 7th 2025
Article

Azacitidine plus venetoclax reduced the risk of progressive disease, persistent disease prompting therapy change, relapse, hospice, or death by 45%.

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Gina Mauro
December 7th 2025
Article

The phase 3 EPCORE FL-1 trial showed that adding epcoritamab to R2 delivered superior PFS and response rates for patients with relapsed/refractory FL vs R2 alone.